BRIEF published on 04/30/2025 at 07:35, 7 months 21 days ago Nicox publie ses résultats financiers pour l'année 2024 Perte Nette Réserves De Trésorerie Résultats Financiers De Nicox Vente De Revenus De VYZULTA Essais NCX 470
BRIEF published on 04/30/2025 at 07:35, 7 months 21 days ago Nicox Reports Full Year 2024 Financials Net Loss Cash Reserves Nicox Financial Results VYZULTA Revenue Sale NCX 470 Trials
PRESS RELEASE published on 04/30/2025 at 07:30, 7 months 21 days ago Nicox : Résultats financiers de l’année 2024 Nicox annonce résultats financiers 2024, incluant CA de 7,9M€, produits exceptionnels de 13,7M€ et trésorerie de 10,5M€. Études cliniques NCX 470 en cours Résultats Financiers Trésorerie Études Cliniques Nicox NCX 470
PRESS RELEASE published on 04/30/2025 at 07:30, 7 months 21 days ago Nicox Provides Full Year 2024 Financial Results Nicox reports €7.9 million revenue for 2024 with exceptional income of €13.7 million from VYZULTA transfer. Cash of €10.5 million and NCX 470 Phase 3 trial results expected in Q3 2025 Financial Results Revenue Nicox NCX 470 VYZULTA
BRIEF published on 03/19/2025 at 07:35, 9 months 2 days ago Nicox a terminé la dernière visite de l'essai de phase 3b NCX 470 sur le glaucome à Whistler Nicox Résultats Cliniques NCX 470 Glaucome Essai De Phase 3b
BRIEF published on 03/19/2025 at 07:35, 9 months 2 days ago Nicox Completes Final Visit for NCX 470 Phase 3b Whistler Glaucoma Trial Glaucoma Nicox Clinical Results NCX 470 Phase 3b Trial
PRESS RELEASE published on 03/19/2025 at 07:30, 9 months 2 days ago Nicoxannonce que la visite finale du dernier patient a été effectuée dans l’étude de phase 3b Whistler sur le NCX 470 pour le glaucome Nicox annonce la fin de la visite du dernier patient dans l'étude de phase 3b Whistler sur le NCX 470 pour le glaucome. Résultats attendus en mai 2025 Étude Clinique Nicox NCX 470 Glaucome Phase 3b
PRESS RELEASE published on 03/19/2025 at 07:30, 9 months 2 days ago Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Nicox completes final patient visits in Phase 3b Whistler Glaucoma Trial for NCX 470, with results expected May 2025. Denali trial in progress, results planned for Q3 2025 Clinical Development Nicox NCX 470 Phase 3b Glaucoma Trial
BRIEF published on 01/28/2025 at 07:35, 10 months 24 days ago Nicox: Participation in Major Congresses in 2025 Investment Ophthalmology Congress Nicox NCX 470
BRIEF published on 01/28/2025 at 07:35, 10 months 24 days ago Nicox : Participation aux Grands Congrès en 2025 Investissement Ophtalmologie Congrès Nicox NCX 470
Published on 12/20/2025 at 00:30, 1 day 11 hours ago Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 1 day 14 hours ago GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 1 day 17 hours ago Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 1 day 21 hours ago Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 1 day 22 hours ago Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF
Published on 12/21/2025 at 08:55, 3 hours 31 minutes ago Vantage Markets recognised for real-time threat intelligence collaboration with Trend Micro
Published on 12/20/2025 at 16:45, 19 hours 41 minutes ago Shanghai Electric Powers Up Iraq's Energy Future with Major 625MW Efficiency Upgrade
Published on 12/20/2025 at 10:05, 1 day 2 hours ago FITUR 2026 highlights the strong synergies between Germany and Spain
Published on 12/19/2025 at 22:03, 1 day 14 hours ago EAMD: Trading resumes on the Düsseldorf Stock Exchange, lawsuit filed by minority shareholders dismissed, capital increase for investments in drone projects in the defense tech sector
Published on 12/19/2025 at 21:40, 1 day 14 hours ago IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries
Published on 12/19/2025 at 21:57, 1 day 14 hours ago Mise à disposition du document d’enregistrement universel
Published on 12/19/2025 at 08:30, 2 days 3 hours ago Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 2 days 3 hours ago Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 2 days 5 hours ago EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 2 days 5 hours ago EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
